Polycythemia differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 150: | Line 150: | ||
* Usually asymptomatic | * Usually asymptomatic | ||
|- | |- | ||
! | !Primary familial and congenital polycythemia<ref>Bento C, McMullin MF, Percy M, et al. Primary Familial and Congenital Polycythemia. 2016 Nov 10. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395975/</ref> | ||
! | !Autosomal dominant inheritance | ||
! | !EPOR mutation | ||
! | !Very rare | ||
! | !+ | ||
! | !+ | ||
! | !+/- | ||
! | !- | ||
! | !- | ||
! | !- | ||
|Facial plethora | |||
! | ! | ||
!- | |||
|Nl to ↑ | |||
!- | |||
!- | |||
!Altered mental status | |||
|↑ | |||
|↑ | |||
!Nl | |||
!Nl | |||
!Nl to ↓ | |||
!NA | |||
!Isolated erythrocytosis + genetic testing | |||
! | ! | ||
* Mild manifestations of hyperviscosity | |||
|- | |||
! | ! | ||
!Disease | |||
!Etiology | |||
!Mutation | |||
!Demography | |||
!Fatigue | |||
!Headache | |||
!Shortness of breath | |||
!Bleeding | |||
!Pain | |||
!Other symptoms | |||
!Appearance | |||
!SaO2 | |||
!Fever | |||
!BP | |||
!Tenderness | |||
!Splenomegaly | |||
!Other signs | |||
!Hb | |||
!RBC | |||
!WBC | |||
!Plt | |||
!EPO level | |||
!PBS | |||
!Gold standard diagnosis | |||
!Associated findings | |||
|- | |- | ||
! rowspan="5" |Iatrogenic causes | ! rowspan="5" |Iatrogenic causes | ||
Line 180: | Line 208: | ||
! | ! | ||
* Reduced plasma volume | * Reduced plasma volume | ||
! | !- | ||
! | !Any | ||
! | !- | ||
! | !- | ||
! | !+ | ||
! | !- | ||
! | !- | ||
! | !- | ||
|[[Cyanosis]] | |||
|↓ | |||
! | !- | ||
! | !Nl | ||
! | !- | ||
! | !- | ||
! | !- | ||
|↑ | |||
|↑ | |||
! | !Nl | ||
! | !Nl | ||
! | !Nl to ↓ | ||
! | !NA | ||
!Clinical manifestation | !Clinical manifestation | ||
! | !NA | ||
|- | |- | ||
!Chronic exposure to carbon monoxide | !Chronic exposure to carbon monoxide | ||
! | ! | ||
* Occupational exposure | * Occupational exposure | ||
! | !- | ||
! | !Miners, fire fighters | ||
!+ | !+ | ||
!+ | !+ | ||
Line 218: | Line 246: | ||
* Headache | * Headache | ||
* Altered cognition | * Altered cognition | ||
|[[Cyanosis]] | |||
|↓ | |||
! | !- | ||
! | !Nl | ||
! | !- | ||
! | !- | ||
! | !- | ||
|↑ | |||
|↑ | |||
! | !Nl | ||
! | !Nl | ||
! | !Nl to ↓ | ||
! | !NA | ||
!Blood level of [[carboxyhemoglobin]] | !Blood level of [[carboxyhemoglobin]] | ||
! | !NA | ||
|- | |- | ||
!Diuretics | !Diuretics | ||
Line 323: | Line 351: | ||
* | * | ||
| align="center" style="background:#F5F5F5;" | - | | align="center" style="background:#F5F5F5;" | - | ||
| | |Depends on etiology | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| | | + | ||
| align="center" style="background:#F5F5F5;" | - | | align="center" style="background:#F5F5F5;" | - | ||
| align="center" style="background:#F5F5F5;" |Depends on etiology | | align="center" style="background:#F5F5F5;" |Depends on etiology | ||
Line 332: | Line 360: | ||
* [[Shortness of breath]] | * [[Shortness of breath]] | ||
| align="center" style="background:#F5F5F5;" |[[Cyanosis]] | | align="center" style="background:#F5F5F5;" |[[Cyanosis]] | ||
| | |↓ | ||
! align="center" style="background:#F5F5F5;" |- | |||
| | |Nl to ↑ | ||
! align="center" style="background:#F5F5F5;" |- | |||
! align="center" style="background:#F5F5F5;" |- | |||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* [[Crackles]] | * [[Crackles]] | ||
Line 346: | Line 374: | ||
| align="center" style="background:#F5F5F5;" |Nl | | align="center" style="background:#F5F5F5;" |Nl | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
! align="center" style="background:#F5F5F5;" |NA | |||
! align="left" style="background:#F5F5F5;" |Clinical manifestation + imaging | |||
| align="left" style="background:#F5F5F5;" | | | align="left" style="background:#F5F5F5;" | | ||
* Variable manifestations given the diverse etiologies | * Variable manifestations given the diverse etiologies | ||
Line 359: | Line 387: | ||
*[[Leiomyoma|Uterine fibroids]] | *[[Leiomyoma|Uterine fibroids]] | ||
| align="center" style="background:#F5F5F5;" | - | | align="center" style="background:#F5F5F5;" | - | ||
| | |Depends on etiology | ||
| align="center" style="background:#F5F5F5;" | + | | align="center" style="background:#F5F5F5;" | + | ||
| align="center" style="background:#F5F5F5;" | - | | align="center" style="background:#F5F5F5;" | - | ||
| | | - | ||
| align="center" style="background:#F5F5F5;" | - | | align="center" style="background:#F5F5F5;" | - | ||
| align="center" style="background:#F5F5F5;" |Depends on etiology | | align="center" style="background:#F5F5F5;" |Depends on etiology | ||
| align="center" style="background:#F5F5F5;" |Depends on etiology | | align="center" style="background:#F5F5F5;" |Depends on etiology | ||
| align="center" style="background:#F5F5F5;" |Chronically ill | | align="center" style="background:#F5F5F5;" |Chronically ill | ||
| | |Nl | ||
| align="center" style="background:#F5F5F5;" | +/- | | align="center" style="background:#F5F5F5;" | +/- | ||
| | |Nl to ↑ | ||
| align="center" style="background:#F5F5F5;" | +/- | | align="center" style="background:#F5F5F5;" | +/- | ||
| align="center" style="background:#F5F5F5;" | +/- | | align="center" style="background:#F5F5F5;" | +/- | ||
Line 380: | Line 408: | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
| align="center" style="background:#F5F5F5;" |↑ | | align="center" style="background:#F5F5F5;" |↑ | ||
! align="center" style="background:#F5F5F5;" |NA | |||
! align="center" style="background:#F5F5F5;" |Clinical manifestation + imaging | |||
| align="center" style="background:#F5F5F5;" | | | align="center" style="background:#F5F5F5;" | | ||
* Variable manifestations given the diverse etiologies | * Variable manifestations given the diverse etiologies |
Revision as of 20:12, 21 August 2018
Polycythemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Polycythemia differential diagnosis On the Web |
American Roentgen Ray Society Images of Polycythemia differential diagnosis |
Risk calculators and risk factors for Polycythemia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Differential Diagnosis of Polycythemia
Polycythemia must be differentiated from a variety of other conditions.[1][2][3]
Category | Disease | Etiology | Mutation | Clinical manifestations | Laboratory findings | Gold standard disgnosis | Associated findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demography | Symptoms | Signs | CBC | EPO level | PBS | ||||||||||||||||||||
Fatigue | Headache | Shortness of breath | Bleeding | Pain | Other symptoms | Appearance | SaO2 | Fever | BP | Tenderness | Splenomegaly | Other signs | Hb | RBC | WBC | Plt | |||||||||
Mutational causes | Polycythemia vera (PV)[4] |
|
JAK2 mutation > 95% | Mean age >60 years old | + | + | + | +/- | Facial plethora | Nl | - | ↑ |
|
+ | ↑ | ↑ RBC mass | Nl to ↑ | Nl to ↑ | ↓ |
|
WHO criteria for PV | ||||
Chuvash polycythemia[5] | Hypoxia-sensing disorder | VHL mutation | Russia, Italy
<40 years old |
+ | + | + | +/- |
|
Facial plethora | ↓ | - | ↑ |
|
+ | ↑ | ↑ | Nl | Nl | ↑ |
|
Molecular genetic testing |
| |||
Hereditary methemoglobinemia[6] |
|
Mutations in globin gene | Infants | +/- | +/- | +/- | - | - | - | Cyanosis | Inaccurately Nl | - | Nl | - | - | Altered mental status | ↑ | ↑ | Nl | Nl | Nl | NA | RBC enzyme activity + DNA analysis |
| |
Primary familial and congenital polycythemia[7] | Autosomal dominant inheritance | EPOR mutation | Very rare | + | + | +/- | - | - | - | Facial plethora | - | Nl to ↑ | - | - | Altered mental status | ↑ | ↑ | Nl | Nl | Nl to ↓ | NA | Isolated erythrocytosis + genetic testing |
| ||
Disease | Etiology | Mutation | Demography | Fatigue | Headache | Shortness of breath | Bleeding | Pain | Other symptoms | Appearance | SaO2 | Fever | BP | Tenderness | Splenomegaly | Other signs | Hb | RBC | WBC | Plt | EPO level | PBS | Gold standard diagnosis | Associated findings | |
Iatrogenic causes | Smoking |
|
- | Any | - | - | + | - | - | - | Cyanosis | ↓ | - | Nl | - | - | - | ↑ | ↑ | Nl | Nl | Nl to ↓ | NA | Clinical manifestation | NA |
Chronic exposure to carbon monoxide |
|
- | Miners, fire fighters | + | + | + | - | - |
|
Cyanosis | ↓ | - | Nl | - | - | - | ↑ | ↑ | Nl | Nl | Nl to ↓ | NA | Blood level of carboxyhemoglobin | NA | |
Diuretics | |||||||||||||||||||||||||
Use of androgens or anabolic steroids |
|
||||||||||||||||||||||||
Self-injection of erythropoietin |
|
||||||||||||||||||||||||
Secondary causes | Secondary polycythemia due to hypoxemia |
|
- | Depends on etiology | + | + | + | - | Depends on etiology | Cyanosis | ↓ | - | Nl to ↑ | - | - | ↑ | ↑ | Nl | Nl | ↑ | NA | Clinical manifestation + imaging |
| ||
Secondary polycythemia due to erythropoietin producing tumor | - | Depends on etiology | + | - | - | - | Depends on etiology | Depends on etiology | Chronically ill | Nl | +/- | Nl to ↑ | +/- | +/- | ↑/↓ | ↑/↓ | Nl | ↑ | ↑ | NA | Clinical manifestation + imaging |
| |||
Hereditary hemorrhagic telangiectasia | Pulmonary arteriovenous malformations | ↑/↓ | ↑/↓ | ||||||||||||||||||||||
Disease | Etiology | JAK2 mutation | Fatigue | Headache | Bleeding | Pain | Other symptoms | Appearance | Fever | Tenderness | Splenomegaly | Other signs | Hb | RBC | WBC | Plt | Erythropoietin level | PBS | Gold standard diagnosis | Associated findings |
References
- ↑ Tefferi A, Barbui T (2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am J Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
- ↑ Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.
- ↑ Jabbour E, Kantarjian H (2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am J Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.
- ↑ Stein, Brady L.; Oh, Stephen T.; Berenzon, Dmitriy; Hobbs, Gabriela S.; Kremyanskaya, Marina; Rampal, Raajit K.; Abboud, Camille N.; Adler, Kenneth; Heaney, Mark L.; Jabbour, Elias J.; Komrokji, Rami S.; Moliterno, Alison R.; Ritchie, Ellen K.; Rice, Lawrence; Mascarenhas, John; Hoffman, Ronald (2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F". Journal of Clinical Oncology. 33 (33): 3953–3960. doi:10.1200/JCO.2015.61.6474. ISSN 0732-183X.
- ↑ Zhou, Amy W.; Knoche, Eric M.; Engle, Elizabeth K.; Ban-Hoefen, Makiko; Kaiwar, Charu; Oh, Stephen T. (2016). "Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia". New England Journal of Medicine. 375 (5): 494–496. doi:10.1056/NEJMc1600337. ISSN 0028-4793.
- ↑ Da-Silva SS, Sajan IS, Underwood JP (August 2003). "Congenital methemoglobinemia: a rare cause of cyanosis in the newborn--a case report". Pediatrics. 112 (2): e158–61. PMID 12897322.
- ↑ Bento C, McMullin MF, Percy M, et al. Primary Familial and Congenital Polycythemia. 2016 Nov 10. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395975/